We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 results on April 23, after market close. In the last reported quarter, ...

While such prolonged holding periods might seem over the top, the histories of Viking and numerous other biotech companies highlight the prudence of a long-term investment strategy, particularly ...

The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Roche Holding AG and Viking Therapeutics. The Motley Fool has a disclosure policy.

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2024 results on Apr 24, after market close. In the last reported quarter, the ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 results on April 23, after market close. In the last reported quarter, the ...